Credit Suisse analyst Alethia Young downgraded Mesoblast (MESO) to Neutral citing caution following the company's break-up with Teva (TEVA). Mesoblast should be able to find a new partner for its chronic heart failure program, but it could take some time, Young tells investors in a research note. She lowered her probability of success for the program to 25% from 40%. The analyst halved her price target for Mesoblast shares to $5 from $10. The shares have been halted since May 31, when they closed at $7.07.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Luminar Technologies (LAZR) 21.68% +6.44, Mesoblast (MESO) 145.03% +2.00, iShares S&P National AMT Free Municipal Bond Fund (MUB) 19.65% +1.21, Stellantis NV (STLA) 1.41% +0.98, Veritone (VERI) 40.08% +0.46, ALTC Acquistion Corp (ALCC) 6.05% +0.44, US Global Jets ETF (JETS) 7.23% +0.36, Nokia (NOK) 3.33% +0.27, Annovis Bio Inc (ANVS) 91.57% +0.16, and Coca Cola (KO) 0.41% +0.16.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."